Blueprint Medicines Reports First Quarter 2017 Financial Results

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/21/2026

1. SPCX
2. NVDA
3. NFLX
4. META
5. ISRG
6. TSLA
7. SMCI
8. GOOGL
9. RTX
10. S

Go back to Blueprint Medicines Reports First Quarter 2017 Financial Results

Blueprint Medicines (BPMC) PT Raised to $52 at Jefferies

May 4, 2017 8:24 AM EDT

Jefferies raised its price target on Blueprint Medicines (NASDAQ: BPMC) to $52.00 (from $42.00) while maintaining a Buy rating.

"With add'l clinical data for 2 lead candidates (BLU-285, BLU-554) in 2017 likely to strengthen their therapeutic potential, and added clarity around approval path for... More

Blueprint Medicines (BPMC) Misses Q1 EPS by 8c

May 3, 2017 7:06 AM EDT

Blueprint Medicines (NASDAQ: BPMC) reported Q1 EPS of ($0.84), $0.08 worse than the analyst estimate of ($0.76).

For earnings history and earnings-related data on Blueprint Medicines (BPMC) click here.

... More